Current position:News > News > Insights
GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
吉满生物
2024-11-06

Novo Nordisk is sticking close to home for its latest GLP-1 deal, signing a $285 million partnership with fellow Danish company Ascendis Pharma to work on new therapeutics for metabolic and cardiovascular diseases.

image.png

Ascendis will provide access to its TransCon technology platform in an effort to find GLP-1 candidates with reduced dosing frequency, according to a Monday press release. The $285 million payment includes an upfront fee plus development and regulatory milestone payments for the lead program, plus royalties. The company is also eligible for $77.5 million in milestones plus sales-based royalties for each additional program.

The lead program is a once-monthly GLP-1 receptor agonist that Novo will initially develop in obesity and type 2 diabetes. The pharma has exclusive rights to later expand to other indications.

Ascendis will lead early development of the product candidates, while Novo will be responsible for the costs. Novo will also handle clinical development through commercialization.

Learn more about our GLP-1R/GCGR/GIPR catalog.



Latest news
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-17
Could GDF15 Become the Next Super Target After PD-1 and GLP-1?
A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.
Current position:News > News > Insights
classify
GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
吉满生物
2024-11-06

Novo Nordisk is sticking close to home for its latest GLP-1 deal, signing a $285 million partnership with fellow Danish company Ascendis Pharma to work on new therapeutics for metabolic and cardiovascular diseases.

image.png

Ascendis will provide access to its TransCon technology platform in an effort to find GLP-1 candidates with reduced dosing frequency, according to a Monday press release. The $285 million payment includes an upfront fee plus development and regulatory milestone payments for the lead program, plus royalties. The company is also eligible for $77.5 million in milestones plus sales-based royalties for each additional program.

The lead program is a once-monthly GLP-1 receptor agonist that Novo will initially develop in obesity and type 2 diabetes. The pharma has exclusive rights to later expand to other indications.

Ascendis will lead early development of the product candidates, while Novo will be responsible for the costs. Novo will also handle clinical development through commercialization.

Learn more about our GLP-1R/GCGR/GIPR catalog.



Message consultation
reset
submit
Message
Message consultation
reset
submit